5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
There are no Transcripts on LPTN.
PR Newswire (Mar 4, 2014)
PR Newswire (Jan 22, 2014)
PR Newswire (Dec 12, 2013)
LPTN vs. ETF Alternatives
Lpath, Inc., is a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies. It has two product candidates that are currently in clinical development, and one in pre-clinical evaluation.
Wednesday, Oct 92013, 12:46 PM|Wednesday, Oct 92013, 12:46 PM| Comment!
Tuesday, Oct 82013, 5:41 PM
Tuesday, Oct 82013, 5:41 PM| Comment!
- Lpath (LPTN) -9.8% AH after warning that Pfizer (PFE) may divest its exclusive option to co-develop LPTN's leading product candidate, iSONEP.
- In current Phase 2 clinical trials, iSONEP is given alone or in combination with other drugs to treat an ocular disease that often leads to blindness.
- The original agreement with PFE included a $14M upfront payment and shared cost of the Phase 2 clinical trial; also, if PFE opted in after more data was obtained, future payments could be received by LPTN.
Friday, Dec 142012, 3:29 PMLpath (LPTN -19.5%) tanks today after announcing a public offering for an undisclosed ammount of shares. Terms weren't disclosed, and the offering is subject to customary market conditions with no assurances as to whether or when it may be complete. Summer Street Research Partners is sole book-running manager for the offering. |Friday, Dec 142012, 3:29 PM| Comment!
Friday, Dec 142012, 12:45 PM
Monday, Aug 272012, 9:31 AMThe FDA lifts a clinical hold on Lpath's (LPTN.OB) iSONEP, an antibody the firm is developing to treat wet AMD and possibly other eye disorders. The FDA placed the hold in January after finding that a contractor was not complying with its regulations, but Lpath has since replaced the supplier. (PR) |Monday, Aug 272012, 9:31 AM| Comment!
Monday, Jul 302012, 9:38 AMLpath's (LPTN.OB) Lpathomab treatment performed well in tests on mice with partially severed spinal cords. Lpath says Lpathomab "reverses much of the damage caused by trauma to the nervous system," bringing scientists closer to finding a treatment for spinal cord injury. The results of the study have been published in the American Journal of Pathology. (PR) |Monday, Jul 302012, 9:38 AM| Comment!
Friday, Jan 272012, 10:12 AMShares of Lpath (LPTN.OB -31.8%) plummet after the biotech company temporarily suspends trials for its PEDigree and Nexus lipidomics-based antibody therapeutics. LPTN says it took the action when it learned its fill/finish contractor was not in FDA compliance for manufacturing requirements. (submitted by M.E. Garza) |Friday, Jan 272012, 10:12 AM| Comment!